# Acemetacin (HKP) — Acitretin (HKP) — Alitretinoin (WKA) — Aripiprazol (LSE) — Aripiprazol TAB) — Atazanavir (HKP) — Atovaquon (SUE) — Baclofen (INF) — Betahistin (TAB, 1) — Betahistin (TAB, 2) — Betain (PUE, PUL) — Betamethason + Salicylsäure (SAL) — Biperiden (TAB) — Budesonid (HVW, KPG) — Budesonid (HKM, KMP) — Carbamazepin (TAB) — Carbimazol (FTA, TAB) — Cilostazol (TAB) — Clobazam (TAB) — Clon

Abschluss eines Generikarabattvertrags für den o.  g.  Wirkstoff.

Source: QUOTA CÔTE — https://quotacote.com/opportunites/acemetacin-hkp-acitretin-hkp-alitretinoin-wka-aripiprazol-lse-aripipra--421f7f07-0006-48e0-a08e-9bced5137f32
Last checked by QUOTA: 2026-10-16
Methodology: https://quotacote.com/a-propos-des-donnees

## Key facts

- Country: Allemagne [FACT]
- Deadline: 2026-11-25 [FACT]
- Last checked by QUOTA: 2026-10-16 [FACT]
- Sector (QUOTA normalisation): Autre [ANALYSIS]
- Summary: QUOTA editorial summary of the source notice [ANALYSIS]

## Entities

- geography: Allemagne
- funder: GWQ ServicePlus AG Gesellschaft für Wirtschaftlichkeit und Qualität bei Krankenkassen
- buyer: GWQ ServicePlus AG Gesellschaft für Wirtschaftlichkeit und Qualität bei Krankenkassen

## Limitations

- QUOTA republishes a normalised summary, not the tender documents themselves.
- Commercial details (source dossier, full deadline history, budget) are reserved for subscribers.